ESTABLISHED SAFETY PROFILE
The Ferriprox® (deferiprone) safety profile has been established in 70+ studies worldwide2
New Ferriprox Twice-A-Day tablets have an established safety profile similar to Ferriprox 500 mg and 1000 mg Three-Times-A-Day tablets.
Ferriprox has 20 years of worldwide post-marketing experience (8 in the US) and over 98,000 patient-years of use.2
Agranulocytosis and neutropenia
- In clinical trials of 642 Ferriprox-treated patients:
– agranulocytosis occurred in 1.7% of patients
– neutropenia occurred in 6.2% of patients - Fatal agranulocytosis can occur with Ferriprox use. Ferriprox can also cause neutropenia, which may foreshadow agranulocytosis
†† Defined as a single drop in neutrophil count below 1.5 x 109/L, which was not confirmed as neutropenia.
Monitoring your patients on Ferriprox is straightforward1,6 :
Absolute neutrophil count (ANC)
Once, at baseline;
and then weekly, on therapy
Establishes patient’s baseline level and addresses the risk of neutropenia, agranulocytosis, and infection.
Serum liver enzymes
Monthly, on therapy
Increased ALT levels were observed in clinical trials. Consider interruption of therapy if there is a persistent increase in serum transaminase levels.
Plasma zinc concentration frequency: If necessary
- Decreased plasma zinc concentrations have been observed in patients on Ferriprox